A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Inclusion Criteria:

1. Written informed consent
2. Aged 18 or above
3. Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.
4. Documented PD-L1 expression by PD-L1 IHC per local report.
5. Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
6. Part C and Part D: No prior I/O treatment for metastatic NSCLC.
7. Part E: No prior treatment for metastatic NSCLC.
8. ECOG performance status of 0 or 1 at enrolment.
9. Life expectancy of ≥ 12 weeks at enrolment.
10. Have at least 1 measurable lesion per RECIST v1.1.
11. Adequate bone marrow, liver and kidney function

Exclusion Criteria:

1. Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
2. Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
3. Previous treatment with an anti-TIGIT therapy
4. Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
5. Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
6. Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted).

Treatment with one previous systemic chemotherapy will be allowed.

1. Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.
2. Symptomatic central nervous system (CNS) metastasis.
3. Thromboembolic event within 3 months prior to enrolment.
4. Other invasive malignancy within 2 years prior to screening.